GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » EV-to-EBIT

Verici Dx (Verici Dx) EV-to-EBIT : -1.62 (As of May. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Verici Dx's Enterprise Value is $18.16 Mil. Verici Dx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-11.19 Mil. Therefore, Verici Dx's EV-to-EBIT for today is -1.62.

The historical rank and industry rank for Verici Dx's EV-to-EBIT or its related term are showing as below:

VRCDF' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.15   Med: 0   Max: 0
Current: -1.6

VRCDF's EV-to-EBIT is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.34 vs VRCDF: -1.60

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Verici Dx's Enterprise Value for the quarter that ended in Jun. 2023 was $22.79 Mil. Verici Dx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-11.19 Mil. Verici Dx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -49.11%.


Verici Dx EV-to-EBIT Historical Data

The historical data trend for Verici Dx's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx EV-to-EBIT Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
EV-to-EBIT
- -10.75 -1.48

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT - -10.75 - -1.48 -

Competitive Comparison of Verici Dx's EV-to-EBIT

For the Diagnostics & Research subindustry, Verici Dx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Verici Dx's EV-to-EBIT falls into.



Verici Dx EV-to-EBIT Calculation

Verici Dx's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=18.155/-11.193
=-1.62

Verici Dx's current Enterprise Value is $18.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-11.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx  (OTCPK:VRCDF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Verici Dx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-11.193/22.78995262
=-49.11 %

Verici Dx's Enterprise Value for the quarter that ended in Jun. 2023 was $22.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-11.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Verici Dx's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines